During the three and nine months ended September 30, 2026, the Company accelerated 9,092 and 124,391 RSUs and recognized $0.1 million and $0.8 million of stock-based compensation expense related to the acceleration and grant of fully vested shares related to the Restructuring Plan, respectively. Refer to Note 5, Restructuring, for additional information.

As of December 31, 2025, the Company had a bonus accrual of $0.7 million that was expected to be paid in cash. During the nine months ended September 30, 2026, the Company amended the bonus terms and settled the liability in shares of common stock. Accordingly, the Company reversed the bonus accrual and recorded the issuance of common stock of $0.7 million in additional paid-in capital.

The Company recorded total stock-based compensation expense of $2.2 million and $8.0 million during the three and nine months ended September 30, 2026, respectively, as compared to $3.1 million and $7.5 million, for the same period in 2025, respectively. The following table summarizes stock-based compensation expense by function for the three and nine months ended September 30, 2026, and 2025:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2026		2025		2026		2025
	(in thousands)				(in thousands)
Cost of revenue	210		402		788		960
Research and development	680		830		2,772		1,650
Selling and marketing	365		354		1,228		1,088
General and administrative	956		1,486		3,254		3,771
	$	2,211	$	3,072	$	8,042	$	7,469

As of September 30, 2026, the Company had unrecognized stock-based compensation expense of $14.3 million which is expected to be recognized over a weighted average period of 2.5 years.